A food safety turnaround finding traction amid heavy investment
- Neogen is focusing on Food Safety and Animal Safety while waiting to close its Genomics sale.
- Food Safety core growth accelerated to 5.8 percent in the fourth quarter.
- Management successfully fixed previous material weaknesses in its internal financial controls.
- Regulatory agencies in Australia and New Zealand are conducting a deeper review of the Genomics sale.
- The company is increasing research spending by 50 percent for fiscal 2027 to develop new products.
Turnaround gaining momentum
Neogen is a turnaround story, and the new team is beginning to show results. The plan focuses on simplifying the company, fixing operations, and investing in higher-value food safety products. Recent quarters show strong execution, with Food Safety core growth accelerating to 5.8 percent. Management also removed a major cloud over the company by successfully fixing material weaknesses in its internal financial controls.
The most compelling part of the story is the renewed focus on organic growth. Management is building a new innovation line for Petrifilm, aiming to release two new versions a year to target new markets beyond traditional food testing. At the same time, Animal Safety has rebounded as the team fixed major supplier disruptions.
The weakest part is near-term profit margin pressure and regulatory delays. The company is increasing research and development investment by 50 percent for fiscal 2027 to fund its innovation plans. Additionally, the planned sale of the Genomics business is facing deeper regulatory reviews in Australia and New Zealand, which could delay the use of those proceeds to pay down debt.
The bull case needs three things to happen together. The Genomics sale must clear regulatory hurdles, the massive Petrifilm manufacturing transition starting in November 2026 must go smoothly, and the planned new products must launch on time. The bear case is simple. The required investments push out margin targets, and the manufacturing transition leaves no room for error.
Tests, consumables, and channel trust
Neogen makes money by selling testing products, safety products, and related services. Many products are used repeatedly by food plants, labs, veterinarians, livestock producers, and animal health customers. That repeat use matters because the company is not only selling machines or one-time projects. Management is now shifting toward selling complete solutions rather than individual products.
Food Safety is the main engine. Customers use Neogen products to test for pathogens, allergens, toxins, sanitation problems, and other risks in food and feed. Rules around food testing and brand risk support long-term demand, and core growth in this segment has been accelerating.
Animal Safety sells items such as rodent control, insect control, veterinary instruments, and biosecurity products. It also still includes Genomics until the Zoetis sale closes. This segment is more exposed to cyclical animal markets and supplier problems, though supply issues have recently stabilized.
The balance sheet is a key part of the story. Neogen carries significant debt from its prior acquisitions. Management plans to use Genomics sale proceeds to repay debt and strengthen its financial position, provided regulators approve the deal.
What Neogen sells
Petrifilm and indicator testing
Petrifilm is a core Food Safety platform used for microbial testing. Management is building a new innovation line to deliver two new versions per year and expand into new consumer categories.
Pathogen detection
These products help food producers and labs detect harmful organisms. This line has helped drive recent Food Safety business growth.
Sample collection and culture media
These products support routine testing work in food plants and labs. They remain a core part of the daily testing workflow.
Natural toxins, allergens, and sanitation tests
These tests help customers check food, feed, and facilities for safety issues. Demand is tied to testing rules and customer quality programs.
Rodent, insect, and biosecurity products
These Animal Safety products help farms, facilities, and animal owners control pests and disease risks. The supply chain has stabilized after recent disruptions.
Veterinary instruments and disposables
Neogen sells tools and supplies used by vets and animal health customers. This product line faces cyclical demand in agricultural markets.
Genomics services
Genomics provides testing services for production and companion animals. Neogen has agreed to sell this business to Zoetis, making it a near-term deleveraging asset.
Food Safety drives the business
Segment mix relies on trailing revenue data. Food Safety represents roughly three quarters of the business, but Genomics remains inside reported segments until the pending Zoetis deal closes.
What could break the plan
Petrifilm transfer disruption
High impact · Medium oddsNeogen is bringing Petrifilm manufacturing in-house, with the transition starting in November 2026. This is central to the Food Safety moat and margin story. If the transfer causes quality issues, backlogs, or lost customers, the bull case weakens fast.
Investment pressures margins
Medium impact · High oddsManagement is increasing research and development investment by 50 percent for fiscal 2027. The goal is to drive long-term organic growth, but this heavy spending will limit near-term profit margin expansion.
Genomics divestiture delays
High impact · Medium oddsThe planned sale of the Genomics business is facing extended regulatory scrutiny from agencies in Australia and New Zealand. If regulators block the deal or demand major remedies, Neogen would be left with a non-core asset and fewer funds to pay down debt.
Supply chain fragility
Medium impact · Medium oddsEarlier in 2026, Animal Safety suffered from severe third-party supplier quality and manufacturing problems. Management says they have resolved the majority of these issues, but supplier reliance remains an inherent risk.
Integration and transition overhang
Medium impact · Medium oddsThe 3M Food Safety acquisition remains a source of operational risk. Prior integration challenges contributed to a large goodwill impairment in fiscal 2025. Moving smaller accounts to e-commerce channels could cause friction and near-term revenue leakage.
In one breath
What does Neogen Corporation do?
Neogen sells food and animal safety products. Its Food Safety products help test food, feed, and facilities for contamination, while Animal Safety products serve vets, farms, livestock producers, and animal health channels.
Why is Neogen selling Genomics?
Management wants to simplify the company and focus on core Food Safety and Animal Safety products. Neogen agreed to sell Genomics to Zoetis and expects to use proceeds to reduce debt, though the deal is currently facing regulatory reviews.
What is Petrifilm, and why does it matter?
Petrifilm is a key Food Safety testing platform that came with the 3M Food Safety business. Neogen wants to bring its manufacturing in-house and speed up innovation with two new versions per year.
What is the biggest near-term risk for Neogen stock?
The clearest near-term risk is execution. Investors need to see the Petrifilm manufacturing move stay on schedule without hurting customers, and margins must hold up during a heavy investment phase.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- September 13, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near Neogen Corporation in Finn's Diagnostics & Research industry ranking.
